255 related articles for article (PubMed ID: 18548994)
1. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Khouri S; Kotliroff A; Lishner M; Amital H
Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
[No Abstract] [Full Text] [Related]
2. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
[No Abstract] [Full Text] [Related]
3. [Adverse effects of imatinib mesylate].
Isshiki I
Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
[No Abstract] [Full Text] [Related]
4. Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Wong M; Sade S; Gilbert M; Klieb HB
Dermatol Online J; 2011 May; 17(5):4. PubMed ID: 21635826
[TBL] [Abstract][Full Text] [Related]
5. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
6. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Al-Kali A; Farooq S; Tfayli A
J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
[TBL] [Abstract][Full Text] [Related]
7. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
8. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
[No Abstract] [Full Text] [Related]
9. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
Woo SM; Huh CH; Park KC; Youn SW
J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
[No Abstract] [Full Text] [Related]
10. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
11. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
12. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
[TBL] [Abstract][Full Text] [Related]
13. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
Busuttil DP
Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
[TBL] [Abstract][Full Text] [Related]
14. Dermatological toxicity of imatinib mesylate.
Prasad N; Deshmukh C; Biswas G; Bakshi A; Sastry PS; Parikh PM
J Assoc Physicians India; 2005 Apr; 53():298. PubMed ID: 15987015
[No Abstract] [Full Text] [Related]
15. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
17. Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.
Ianotto JC; Tempescul A; Amet Y; Grall P; Dalbies F; Eveillard JR; Guillerm G; Berthou C
Am J Hematol; 2012 Apr; 87(4):437-9. PubMed ID: 22287505
[No Abstract] [Full Text] [Related]
18. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
[No Abstract] [Full Text] [Related]
19. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib.
Steele JC; Triantafyllou A; Rajlawat BP; Field EA
Clin Exp Dermatol; 2012 Jun; 37(4):432-3. PubMed ID: 22420895
[No Abstract] [Full Text] [Related]
20. Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy.
Yu YH; Shere Y; Vigneswaran N
Tex Dent J; 2012 Aug; 129(8):764-5, 786-8. PubMed ID: 22988661
[No Abstract] [Full Text] [Related]
[Next] [New Search]